Abstract
Introduction: Dravet Syndrome is a complex neurological disorder that begins in the first months of life due to a mutation in the SCN1A gene. This syndrome is pharmacoresistant and requires specific medications to prevent worsening in the development of these children. Cannabidiol is a phytocannabinoid extracted from the Cannabis sativa plant that acts as a modulator in the endocannabinoid system. Objective: To compare conventional drugs with cannabidiol, their side effects, and the quality of life of patients after using cannabidiol. Method: This is an integrative literature review. The sources used were PubMed, ScienceDirect, and SCIELO. The searches were conducted using the descriptors: Cannabidiol, Dravet Syndrome, epilepsy, SCN1A gene mutation, CBD efficacy, mechanism of action, conventional drugs. Results: Of the 64 selected articles, 26 reported a significant reduction in seizure frequency; 6 did not yield favorable results regarding the use of cannabidiol in epilepsy treatment; 12 showed long-term efficacy of cannabidiol use; 12 reported benefits of cannabidiol use in children with Dravet Syndrome; and 8 indicated an improvement in quality of life. Conclusion: There is significant progress that cannabidiol has brought to patients with Dravet Syndrome, improving the quality of life for both patients and their caregivers. However, more studies, especially long-term, need to be conducted.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call